NCT04837092View on ClinicalTrials.gov

Phase I/II Study of FR104 First Administration in Patient with Renal Transplantation: FIRsT Study

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Kidney Transplantation

Interventions

DRUG

FR104

FR104 treatment administration at day 0, day 14 then every 28 days until month 12

Trial Locations (1)

Unknown

Blancho, Nantes

Sponsors

Collaborators (1)

OSE Immunotherapeutics

All Listed Sponsors

collaborator

OSE Immunotherapeutics

INDUSTRY

lead

Nantes University Hospital

OTHER